terraplasma medical is pleased to announce the exclusive cooperation for the distribution of the plasma care® product line in Eastern Europe.
Cold atmospheric plasma inactivates bacteria, viruses, fungi and also multi-resistant pathogens. It activates cell growth, blood circulation and cell metabolism, thus stimulating wound healing. Its use in medical technology is a quantum leap for the treatment of acute and chronic wounds as well as dermatological skin diseases. It revolutionizes, supplements and replaces conventional treatment methods, for example in surgery to prevent postoperative infections. In nursing, it offers a treatment option for chronic, often long-standing and non-healing wounds. Cold plasma therapy reduces the use of antibiotics or cortisone and causes neither allergic side effects nor pain.
Widespread use of plasma care® in clinics, care facilities, and private practices
The plasma care® product line developed by terraplasma medical GmbH for this purpose will in future be distributed exclusively by an established and widely positioned consortium in Eastern Europe. The aim of the cooperation is the widespread use of the plasma care® product line in clinics and care facilities, as well as by physicians in private practices in Eastern Europe. To this end, exclusive distribution agreements have already been signed for Poland and Hungary with substantial purchase commitments of several million EUR, and other countries will follow shortly.
With this cooperation, research and development and a strong distribution are joining forces. Jens Kirsch, CEO of terraplasma medical GmbH, is looking forward to the sales cooperation: “In addition to our already established markets, we can now also achieve a broad market breakthrough in Eastern Europe for plasma medicine and our plasma care® products.”
terraplasma medical GmbH, based in Garching near Munich, was founded in 2016 by terraplasma GmbH, a spin-off from the Max Planck Society. The idea: to use the antimicrobial and tissue-regenerating effect of cold plasma in medicine with a small handheld device for stationary and mobile use. In 2019, plasma care® was approved for the treatment of chronic wounds, and in 2021 plasma derma care® for the treatment of skin diseases induced by bacteria and fungi. Currently, terraplasma medical is researching and developing further clinical application areas like dentistry and respiratory tract infections.
terraplasma medical GmbH
Jens Kirsch (CEO)
85748 Garching b. München